Population-based carrier screening for cystic fibrosis: a systematic review of 23 years of research.
systematic_review · Level I
Where this comes from
- Record sourced from PubMed, PMID 24030436.
- Also identified by DOI 10.1038/gim.2013.125.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Cystic fibrosis is the most common severe autosomal recessive disease, with a prevalence of 1 in 2,500-3,500 live births and a carrier frequency of 1 in 25 among Northern Europeans. Population-based carrier screening for cystic fibrosis has been possible since CFTR, the disease-causing gene, was identified in 1989. This review provides a systematic evaluation of the literature from the past 23 years on population-based carrier screening for cystic fibrosis, focusing on the following: uptake of testing; how to offer screening; attitudes, opinions, and knowledge; factors influencing decision making; and follow-up after screening. Recommendations are given for the implementation and evaluation of future carrier-screening programs.
Medical subject headings
- Cystic Fibrosis
- Genetic Carrier Screening
- Genetic Testing